Releases Geral
BioPharmaSpec Announces Major Investments in Mass Spectrometry and Related Instrumentation
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 3 de junho de 2024
BioPharmaSpec
MALVERN, Pa. and ST. SAVIOUR, Jersey, June 03, 2024 (GLOBE NEWSWIRE) — BioPharmaSpec (BioPharmaSpec), the leading global Contract Research Organization (CRO) for discovery and preclinical characterization of biopharmaceuticals, has made major new investments in instrumentation, including top-of-the-range Mass Spectrometers, to support its clients in their product development goals.
On June 1st, 2024, BioPharmaSpec announced that it had recently purchased a range of new Mass Spectrometry instrumentation, including: Waters Select Series CYCLIC Ion Mobility Separation (IMS) High Definition LC-MS/MS with ECD, SCIEX ZenoTOF 7600 LC-MS/MS with EAD, Waters Xevo TQ Absolute and Waters Xevo G3 LC-MS/MS Q-TOFs.
To further support Clients with the provision of their first-class characterization services, BioPharmaSpec has also expanded its overall analytical instrumentation portfolio with the Bio-Techne (Protein Simple) Maurice Flex icIEF, CE-SDS and cIEF instrument, two Shimadzu PPSQ-53A Gas Phase Sequencers and a Wyatt DAWN Ambient 18 angle Multi Angle Light Scattering with Integrated DLS and Optilab dRI detector.
The instruments currently being installed and qualified across BioPharmaSpecs global laboratories further enhance BioPharmaSpecs already impressive mass spectrometric, chromatographic and spectroscopic service provision.
About BioPharmaSpec
BioPharmaSpec is a CRO specializing in the structural characterization and physicochemical analysis of recombinant biopharmaceuticals, including biosimilars and biobetters, monoclonal antibodies, Antibody Drug Conjugates (ADCs), gene therapy products (i.e. AAV- based therapies), peptides, oligonucleotides and many more product types, with a focus on discovery, early and pre-clinical phases.
Contact:
Lindsay McGowan, Director of Business Development, BioPharmaSpec
Email: l.mcgowan@biopharmaspec.com
For more information, visit https://biopharmaspec.com/
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda
19 de outubro de 2023Sabin Vaccine Institute WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus.
Saiba Mais -
Releases Geral Imobiliária auxilia na busca por imóveis ideais para pets
28 de março de 2024rio de janeiro - rj--(DINO - 28 mar, 2024) - Atualmente, a integração de animais de estimação como membros das famílias reflete uma alteração profunda nas estruturas sociais e fam
Saiba Mais -
Releases Geral Global Africa Business Initiative announces line up for 2024 flagship event Unstoppable Africa: The Solution for a Global Future
5 de setembro de 2024New York, United States of America, Sept. 05, 2024 (GLOBE NEWSWIRE) -- The Global Africa Business Initiative (GABI) has announced its line up and programme for its annual
Saiba Mais